Remedent (REMI) Rating Increased to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Remedent (OTCMKTS:REMI) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning.
According to Zacks, “REMEDENT, INC., a publicly-traded company on the OTCBB, specializes in the research, development, manufacturing and marketing of oral care and cosmetic dentistry products. With offices in California, Belgium and Singapore, Remedent distributes its products in more then thirty five countries. “
REMI opened at $0.26 on Wednesday. The stock has a market cap of $5.20 million, a price-to-earnings ratio of 8.67 and a beta of -0.76. Remedent has a 52-week low of $0.14 and a 52-week high of $0.34.
Remedent, Inc, through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping.
Featured Story: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Remedent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Remedent and related companies with MarketBeat.com's FREE daily email newsletter.